Enanta Pharmaceuticals (ENTA) PT Lowered to $50 at RBC Capital
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Price: $11.88 -1%
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $50.00 (from $52.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
- H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
- Akamai Technologies (AKAM) PT Raised to $149 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
